PMM.11 Audit of identification of antenatal risk factors for pre-eclampsia

    loading  Checking for direct PDF access through Ovid

Abstract

Background

The Centre for Maternal and Child Enquires Saving Mother’s Lives report, 2006–2008, ranks preeclampsia second in the direct causes of maternal death in the UK.1 Preeclampsia is associated with increased perinatal mortality. NICE clinical guideline 107: Hypertension in Pregnancy, indicates patients with defined risk should receive aspirin 75mg daily or serial ultrasound for fetal growth and umbilical Doppler assessment every 4 weeks from 28–30 weeks gestation.2

Aims/Objectives

To assess if women with identifiable risk factors for preeclampsia at the booking appointment are being appropriately managed according to NICE guidance.

Materials/Methods

A 50 day, prospective data collection of all deliveries in a tertiary referral centre. 846 charts included, 25 charts not located. Notes were reviewed for evidence of appropriate management in patients with risk factors for pre-eclampsia. Notes were reviewed to identify those who developed hypertension.

Results

821 charts were reviewed. 117 patients had risk factors for preeclampsia, 100 requiring aspirin 75mg, 12 requiring serial growth scans and umbilical artery Doppler assessment and 5 requiring both interventions. 33 out of 117 cases were managed appropriately.

Results

14 patients with risk factors developed pre-eclampsia which required induction of labour or caesarean section, of these, 6 had not been risk managed appropriately.

Summary/ Conclusions

Booking appointments could be better utilised to identify those at risk of developing preeclampsia, institute appropriate management and ultimately improve obstetric outcome. Staff education on guidance and review of booking interview structure is advised to ensure these patients are correctly identified. We plan to re-audit in 1 year.

Related Topics

    loading  Loading Related Articles